Peptide Therapeutics Market

The global market for peptide therapeutics reached a value of USD 42.05 billion in 2022 and is projected to grow at a CAGR of 6.3% from 2023 to 2030. The increasing prevalence of cancer and metabolic disorders such as osteoporosis, obesity, and diabetes will drive the adoption of peptide therapeutics during the forecast period. There is a high demand for cost-effective drugs due to the growing number of pediatric patients and the pervasiveness of target diseases in low-income countries. Peptide therapeutics are also being explored as treatments for COVID-19, with researchers searching for compounds that can block the mechanisms involved in infection or treat the resulting conditions.

On February 21, 2020, the Food and Drug Administration expanded the definition of biologics to include chemically synthesized polypeptides larger than 40 amino acids but less than 100 amino acids, as well as synthetic peptides with 40 or fewer amino acids. This recognition of peptide drugs as potential COVID-19 treatments is expected to have a positive impact on the market.

The COVID-19 pandemic caused significant disruptions to clinical trials in the United States, affecting the healthcare sector. Many organizations involved in drug research had to relocate to remote working environments, leading to interruptions in non-COVID-19 experiments. Consequently, COVID-19 is expected to have a greater influence on the non-COVID-19 peptide therapeutics market during the global epidemic.

Increased investments in drug discovery are directly contributing to market growth. Peptide therapeutics research and development primarily focuses on oncology, infectious diseases, metabolic disorders, and diabetes. The presence of a strong product pipeline and advancements in peptide manufacturing processes are expected to further drive market growth.

Companies are undertaking initiatives to develop new drug candidates and engage in extensive R&D to maintain their market position. The number of clinical trials for peptide therapeutics has significantly increased over the past decade, propelling growth in the forecast period. Partnerships and collaborations, such as the one between Amgen and Generate Biomedicines, contribute to the development of novel protein therapeutics.

Chronic diseases, including cancer, diabetes, and cardiovascular diseases, are major causes of morbidity and mortality worldwide. The rising prevalence of chronic diseases increases the demand for effective therapeutics, but the market growth may be limited by challenges in peptide therapeutics development, increasing costs, and strict regulatory requirements.

Application Insights
In terms of applications, the metabolic segment dominated the market in 2022, driven by the increasing prevalence of metabolic disorders and the growing geriatric population. Cancer emerged as the second-largest segment, with rising cancer rates and the prescription of peptide therapeutics for cancer treatment. The demand for fast-acting and efficient therapeutics, along with awareness of chemotherapy and radiation therapy side effects, contributes to the growth of peptide-based drugs in the cancer segment.

Type Insights
In 2022, the innovative segment dominated the market with a revenue share of over 61.8%. This was attributed to the significant R&D investments made by large pharmaceutical companies for the discovery and development of new drugs, as well as high prescription rates. The market is categorized into generic and innovative segments based on type.

The generic segment is expected to experience rapid growth during the forecast period. Increased healthcare spending, particularly in federal government healthcare, is anticipated to drive the adoption of generic drugs. The expiration of patents on many branded drugs is also a key factor contributing to the growth of the generic segment. Patent expiration presents a significant opportunity for generic players to enter the market with lower-cost alternatives to blockbuster drugs. However, brand loyalty may have an impact on the growth of the generic segment for some innovative drugs.

Manufacturer Type Insights
In 2022, the in-house manufacturing segment held the largest revenue share of over 65.1%. This is because most key players prefer to develop peptide therapeutics in-house due to stringent regulations and the high cost associated with outsourcing. Large pharmaceutical companies have the necessary infrastructure and advanced technology for large-scale production, making in-house manufacturing the preferred choice.

Outsourcing activities for manufacturing are also expected to grow in the forecast period due to the challenges in manufacturing therapeutics with high-quality standards. Companies prefer to outsource the active pharmaceutical ingredient (API) to companies that have expertise and advanced technology for manufacturing various types of peptides.

Peptide manufacturing is a complex process that requires advanced technologies such as Solid-Phase Peptide Synthesis (SPPS), Liquid-Phase Peptide Synthesis (LPPS), or Hybrid for purification and synthesis of high-quality products. These factors contribute to the high cost of manufacturing. Furthermore, increasing R&D funding and capital investments by key players through strategic agreements are expected to drive market growth in the forecast period.

Route of Administration Analysis
In 2022, the parenteral route of administration dominated the market with a revenue share of over 80.0%. This can be attributed to its high adoption rate, faster drug delivery, and ease of application. Biopharmaceutical companies are continuously exploring new methods of drug delivery specifically for peptides. Novel drug delivery technologies are being evaluated for their efficacy in improving drug delivery performance and patient compliance, such as engineered molecules with advanced PEGylation. The oral route of drug administration offers advantages in terms of patient compliance and acceptability. However, enzymatic degradation that hinders the absorption of these drugs into the bloodstream poses a major disadvantage.

The pulmonary route of administration is commonly used for peptide and protein administration due to the physiological characteristics of the respiratory system. Several proteins and peptides are currently undergoing clinical trials and awaiting approval for pulmonary usage. However, low bioavailability and the challenge of smaller molecules crossing the alveolar epithelium and causing inflammation are significant barriers to usage.

Synthesis Technology Analysis
In 2022, the LPPS segment dominated the market with a share of over 45.6% due to the increasing demand for pure peptides in the development of effective therapeutics. However, issues such as longer synthesis time have led consumers to prefer faster and more efficient methods like SPPS.

SPPS reduces synthesis time and is utilized in a wide range of production processes. It offers higher efficiency in synthesizing longer peptides, which drives market demand. Additionally, the associated benefits of automation, scalability, and enhanced control over the physicochemical properties of peptides are expected to fuel market growth in the forecast period.

Hybrid technology is expected to experience lucrative growth in the coming years due to its compatibility with both liquid-phase synthesis and solid-phase synthesis. Companies are investing in R&D to combine the advantages of LPPS and SPPS, providing a cost-effective and sustainable solution

Regional Analysis
In 2022, North America emerged as the dominant region in the market with a revenue share of over 45.9%. Factors such as increased awareness of peptide therapeutics products, growing demand for diagnostics in cancer and other diseases, and the expanding biotechnology industry contribute to the regional market's growth. Additionally, increased government spending on research and development is expected to further support the prominence of peptide therapeutics in the forecast period. The well-established biopharmaceutical and pharmaceutical industry in this region plays a significant role in driving growth. According to the American Cancer Society, it is projected that there will be approximately 1.9 million new cancer cases in the U.S. in 2022, making cancer the second leading cause of death after heart disease. These statistics indicate that peptides will play an increasingly important role in the healthcare sector in the U.S. and will continue to progress through clinical trials. Moreover, as cancer becomes more prevalent, the demand for peptide therapeutic approaches is expected to rise.

The Asia Pacific region is anticipated to witness significant growth during the forecast period due to untapped opportunities, low raw material costs, a growing base of companies offering outsourcing services, a thriving biotech industry, and increased investments in research and development. The lower cost of raw materials and the expiration of patents on blockbuster drugs are expected to boost the generic market in the near future, creating significant growth potential.

Key Companies and Market Share Analysis
Companies in the market employ strategies such as developing new products and technological advancements to gain a competitive position. Additionally, increasing collaborations for conducting trials of new drugs are expected to intensify competitive rivalry. For example, in March 2023, Ono Pharmaceuticals and PeptiDream announced a collaboration for the discovery and development of Macrocyclic Constrained Peptide Therapeutics. In May 2022, LOTTE Corporation acquired Bristol Myers Squibb's production plant in East Syracuse, New York, to establish its novel biologics CDMO business in the U.S. In February 2022, Amgen and Plexium, Inc. entered into a research collaboration and license agreement to develop new targeted protein degradation therapeutics. These partnerships leverage the expertise of each company to drive the development of innovative therapeutics.

Furthermore, companies are seeking additional indications for already approved drugs to expand their market share. For instance, in April 2023, the U.S. FDA approved somapacitan-beco injection for an expanded indication in children aged 2.5 years and older with growth hormone deficiency (GHD).

Some prominent players in the global peptide therapeutics market include Eli Lilly and Company, Pfizer Inc., Amgen Inc., Takeda Pharmaceutical Company Limited, AstraZeneca, Teva Pharmaceutical Industries Ltd., Sanofi, F. Hoffmann-La Roche Ltd, Novartis AG, Novo Nordisk A/S, GlaxoSmithKline plc., Ironwood Pharmaceuticals, Inc., Radius Health, Inc., and Ipsen Pharma.

Global Peptide Therapeutics Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, MarketDigits has segmented the global peptide therapeutics market report based on application, type, type of manufacturer, route of administration, synthesis technology, and region:
 

Application Outlook (Revenue, USD Billion, 2018 - 2030)
• Cancer
• Metabolic Disorders
• Cardiovascular Disorders
• Respiratory Disorders
• Gastrointestinal Disorders
• Infectious Diseases
• Pain
• Dermatological Disorders
• Neurological Disorders
• Renal Disorders
• Others
 

Type Outlook (Revenue, USD Billion, 2018 - 2030)
• Generic
• Innovative
 

Type Of Manufacturers Outlook (Revenue, USD Billion, 2018 - 2030)
• In-house
• Outsourced
 

Route Of Administration Outlook (Revenue, USD Billion, 2018 - 2030)
• Parenteral Route
• Oral Route
• Pulmonary
• Mucosal
• Others
 

Synthesis Technology Outlook (Revenue, USD Billion, 2018 - 2030)
• Solid Phase Peptide Synthesis (SPPS)
• Liquid Phase Peptide Synthesis (LPPS)
• Hybrid Technology
 

Regional Outlook (Revenue, USD Billion, 2018 - 2030)
• North America
• U.S.
• Canada
• Europe
• UK
• Germany
• France
• Spain
• Italy
• Denmark
• Sweden
• Norway
• Asia Pacific
• Japan
• China
• India
• South Korea
• Australia
• South Korea
• Latin America
• Brazil
• Mexico
• Argentina
• Chile
• Middle East & Africa
• South Africa
• UAE
• Saudi Arabia
• Kuwait